ClinicalTrials.gg
RecruitingNCT06281756Updated Nov 10, 2025

Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia

An Early Phase 1 interventional study of Cognitive Behavioral Treatment for Insomnia (CBT-I) and Trazodone in Insomnia, Insomnia Chronic and Insomnia, Primary, sponsored by Milton S. Hershey Medical Center. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Milton S. Hershey Medical Center · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders — 4 open to participants now, 4 under way, none of them phase 3. Trazodone · Sleep Initiation and Maintenance Disorders.

Planned enrollment
4th of 12
600 · median 146
Started
2024
the only one that year
Phase 1
Only one
of the 12
Registered
9th of 12
by date
Lead sponsor
2 of 12
Milton S. Hershey Medical Center

Among the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders, this one is the 4th largest by planned enrollment, is the only one that started in 2024, is the only one in phase 1, and was the 9th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

4 of the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About trazodone

Trazodone: first FDA approval 1981 (DESYREL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

Individuals who have insomnia with short sleep duration (ISS) differ from individuals who have insomnia with normal sleep duration (INS) in terms of health risks (i.e., hypertension) and treatment response. This study will examine whether patients with ISS and INS demonstrate a differential response to two common insomnia treatments. One is behavioral, Cognitive Behavioral Therapy for Insomnia (CBT-I). The other is a widely prescribed, non-habit-forming medication, trazodone used at a low dose. The investigators' findings could lead to evidence-based treatment guidelines that help clinicians more effectively match treatments to insomnia patients and reduce associated health problems.

03

Conditions studied

  • Insomnia
  • Insomnia Chronic
  • Insomnia, Primary
  • Blood Pressure
  • Blood Pressure, High

Keywords

  • sleep
  • sleep disorder
  • insomnia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Able to read and effectively communicate in English at the United States sites or able to read and effectively communicate in English or French at the Canadian site.
  • Meets criteria for chronic insomnia
  • (BMI) 18.5 kg/m2 and higher

Exclusion criteria

Exclusion Criteria:

  • Age \< 18
  • Unable to read and effectively communicate in English at the United States sites or able to read and effectively communicate in English or French at the Canadian site.
  • Unwilling to share email address/cell phone number to accept survey links.
  • Life time diagnosis of psychotic or bipolar disorder
  • History of severe apnea or an Apnea Hypopnea Index (AHI) ≥15 that is not currently treated with Positive Airway Pressure (PAP) therapy, an oral device or an implanted device, or was not treated with surgery or weight loss.
  • Started new or changed treatment for sleep apnea in the past three months
  • Does not meet criteria for chronic insomnia
  • Meets criteria for narcolepsy or hypersomnia disorder
  • Meets criteria for circadian rhythm disorder (including night shift work)
  • Unstable medical conditions that would make participation unsafe or unfeasible
  • Falls resulting in hospitalization, significant injury or fracture within past 12 months
  • 2 hospitalizations or emergency room visits within past 12 months for chronic conditions
  • Active chemotherapy or radiation therapy for cancer
  • Lifetime diagnoses/treatment of chronic renal failure, hepatic insufficiency, chronic heart failure
  • Does not agree to refrain from other treatments for insomnia beyond what is offered in this study
  • less than 18.5
  • Substance abuse or dependence in the past 12 months
  • Current use of prescription or over the counter medications taken for sleep greater than 2 times per week
  • Current use of systemic or opiate medications
  • Current pregnancy or breastfeeding; plans to get pregnant or unwillingness to use for the length of the study
  • Current use of medications with trazodone
  • Sleep apnea or periodic leg movement disorder as determined by sleep study
  • Blood Pressure levels defined as seated SBP greater than 180 or DBP greater than 110 mmHg
  • interval greater than or equal to 500 ms
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
600 participants (estimated)

Study arms

  • Placebo comparator
    Subjects treated with Cognitive Behavior Treatment for Insomnia (CBT-I) with placebo

    Subjects with insomnia treated with Cognitive Behavior Treatment for Insomnia (CBT-I) for 8 weeks, then non-remitting subjects received placebo for 8 weeks.

    Behavioral: Cognitive Behavioral Treatment for Insomnia (CBT-I) · Other: Placebo

  • Active comparator
    Subjects treated with Cognitive Behavior Treatment for Insomnia (CBT-I) with Trazodone

    Subjects with insomnia treated with Cognitive Behavior Treatment for Insomnia (CBT-I) for 8 weeks, then non-remitting subjects received trazodone for 8 weeks.

    Behavioral: Cognitive Behavioral Treatment for Insomnia (CBT-I) · Drug: Trazodone

Interventions

  • BehavioralCognitive Behavioral Treatment for Insomnia (CBT-I)

    Subjects will receive therapy for 8 weeks

  • Non-remitting subjects will receive Trazodone (dosage) for 8 weeks

  • OtherPlacebo

    Non-remitting subjects will receive placebo for 8 weeks

06

What researchers measure

Primary outcomes

  1. Remission of insomnia symptoms following Cognitive Behavioral Therapy for Insomnia (CBT-I)

    Based on Insomnia Severity Index (ISI) published criteria; 0-28, with 0 being mild and 28 being severe

    Time frame: 9 weeks

  2. Remission of insomnia symptoms following trazodone/placebo Randomized Controlled Trial (RCT)

    Based on Insomnia Severity Index (ISI) published criteria; 0-28, with 0 being mild and 28 being severe

    Time frame: 9 weeks

  3. Remission of insomnia symptoms 6 months following completion of CBT-I Or RCT Treatment

    Based on Insomnia Severity Index (ISI) published criteria; 0-28, with 0 being mild and 28 being severe

    Time frame: 35 weeks

Secondary outcomes

  1. Insomnia Severity Index (ISI) Score following CBT-I

    0-28, with 0 being mild and 28 being severe

    Time frame: 9 weeks

  2. Polysomnography (PSG) Sleep efficiency following Cognitive Behavioral Therapy for Insomnia (CBT-I)

    Polysomnography (PSG) Sleep efficiency measured as a percentage of time asleep during sleep study

    Time frame: 9 weeks

  3. Actigraphy Sleep efficiency following Cognitive Behavioral Therapy for Insomnia (CBT-I)

    Actigraphy Sleep efficiency measured as estimated sleep time at home (2 week period)

    Time frame: 9 weeks

  4. Evening Cortisol levels following CBT-I

    Cortisol levels measured in saliva collected following CBT-I

    Time frame: 9 weeks

  5. Insomnia Severity Index (ISI) Score following RCT

    0-28, with 0 being mild and 28 being severe

    Time frame: 9 weeks

  6. PSG Total Sleep Time (TST) following RCT

    PSG Total Sleep Time measured in minutes asleep during sleep study following RCT

    Time frame: 9 weeks

  7. Actigraphy Total Sleep Time (TST) following RCT

    Actigraphy Total Sleep Time measured in minutes asleep during home study following RCT

    Time frame: 9 weeks

  8. Home Blood Pressure (HBP) Morning Systolic Blood Pressure (SBP)

    Morning SBP Blood Pressure Readings measured at home (7 day period)

    Time frame: 9 weeks

  9. Home Blood Pressure (HBP) Morning Diastolic Blood Pressure (DBP)

    Morning DBP Blood Pressure Readings measured at home (7 day period)

    Time frame: 9 weeks

  10. Evening Cortisol levels following RCT

    Cortisol levels measured in saliva collected following RCT

    Time frame: 9 weeks

  11. Evening Cortisol levels 6 months following completion of CBT-I or RCT Treatment

    Cortisol levels measured in saliva 6 months following CBT-I Or RCT Treatment

    Time frame: 35 weeks

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The investigators have extensive experience preparing data and documentation to be available for public. They agree to abide by the principles for sharing research resources described by the National Heart, Lung, Blood Institute (NHLBI). A copy of the data will be uploaded to the NHLBI Biologic Specimen and Data Repositories Information Coordinating Center (BioLINCC) repository. The datasets will not include any personal identifiers related to participants or clinical sites. Dates will be de-identified through a date-shifting algorithm to mask actual dates while maintaining a relation to the epoch in which events occurred. Data tables will be exported in comma-separated format, readable by statistical software. Variable dictionaries and code books, detailing variable description, format, value domain and labels, will be produced. Raw data files for polysomnogram/actigraphy/cortisol will also be made available, ensuring that data are linkable to study data and data are de-identified.

Supporting information: Study protocol, Analytic code

Time frame: Data collected for aim 1 (an observational study) and aim 2 (a randomized clinical trial) will be made available no more than 3 years after the completion of the last follow-up assessment. Data will be submitted to the Program Officer and uploaded to the NHLBI BioLINCC repository no later than 3 years after the end of clinical activity or 2 years after the main outcomes paper is published, whichever comes first.

Access criteria: NHLBI BioLINCC repository

Data sharing details ↗ · biolincc.nhlbi.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Nov 2027, 44 months after the start.

Of 39 phase 1 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Feb 28, 2024
StartActual
Mar 20, 2024
Primary completionEst.
Nov 30, 2027
CompletionEst.
May 31, 2028
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06281756
Responsible party
Alexandros Vgontzas (Professor, Department of Psychiatry, Milton S. Hershey Medical Center) — Principal investigator
First posted
Feb 28, 2024
Start date
Mar 20, 2024
Primary completion
Nov 30, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Nov 10, 2025

Study contacts

Carrie Criley
Contact
ccriley@pennstatehealth.psu.edu
717-531-4123
Alexandros Vgontzas, MD
principal investigator · Professor, Psychiatry

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trazodone

Start the discussion